Please check your internet connection and try again.
# Linagliptin
## Overview
Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin hormone levels, which stimulate insulin release in a glucose-dependent manner and decrease glucagon levels. It is unique among DPP-4 inhibitors as it is primarily excreted via the enterohepatic system rather than the kidneys.
## Primary Indications
Adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus (T2DM).
## Adult Dosing
Standard dose: 5 mg orally once daily.
Maximum dose: 5 mg daily.
## Pediatric Dosing
Safety and efficacy have not been established in patients younger than 18 years.
## Dose Adjustments
* **Renal Impairment:** No dosage adjustment is required for patients with renal impairment (even in end-stage renal disease).
* **Hepatic Impairment:** No dosage adjustment is required for patients with hepatic impairment.
## Contraindications
* History of a serious hypersensitivity reaction to linagliptin (e.g., anaphylaxis, angioedema, exfoliative skin conditions).
* Type 1 diabetes or treatment of diabetic ketoacidosis (not indicated).
## Adverse Effects
* **Common:** Nasopharyngitis, hypoglycemia (when used with insulin or secretagogues).
* **Serious:** Acute pancreatitis (discontinue if suspected), bullous pemphigoid, severe and disabling arthralgia, hypersensitivity reactions.
## Key Drug Interactions
* **Strong CYP3A4/P-gp Inducers (e.g., Rifampin):** May decrease linagliptin efficacy. If co-administration is necessary, consider alternative agents or monitor glycemic control closely, as linagliptin levels may be reduced.
* **Insulin/Sulfonylureas:** Increased risk of hypoglycemia; a dose reduction of the insulin or secretagogue may be required.
## Monitoring
* **HbA1c:** Typically every 3 to 6 months.
* **Blood Glucose:** Periodic self-monitoring.
* **Signs/Symptoms:** Monitor for skin lesions (bullous pemphigoid), severe joint pain, and symptoms of pancreatitis (persistent, severe abdominal pain).
## Clinical Pearls
* **Renal Advantage:** Often preferred in patients with chronic kidney disease (CKD) because it does not require renal dose adjustments.
* **Administration:** May be taken with or without food.
* **Weight:** Considered weight-neutral, making it a favorable option for patients with obesity.
* **Combination:** Frequently used in combination with metformin or SGLT2 inhibitors.
***
*Disclaimer: This information is for educational purposes only. Clinical practice guidelines and drug information can change frequently. Always verify the most current prescribing information (package insert) and institutional protocols before prescribing or administering medication.*
